Skip to main content
Theranexus logo

Theranexus — Investor Relations & Filings

Ticker · ALTHX ISIN · FR0013286259 LEI · 969500BFCV6IC7MFQP20 PA Manufacturing
Open in API
Filings indexed 286 across all filing types
Latest filing 2022-04-25 Earnings Release
Country FR France
Listing PA ALTHX

About Theranexus

https://www.theranexus.com/en/

THX Pharma (formerly Theranexus) is an innovative, clinical-stage biopharmaceutical company that emerged from the French Alternative Energies and Atomic Energy Commission (CEA). The company specializes in developing treatments for rare neurological disorders. It leverages a unique platform for the identification and characterization of advanced therapy drug candidates. Its lead program is a drug candidate in clinical development for Batten disease, a rare neurodegenerative disorder.

Recent filings

Filing Released Lang Actions
Theranexus publie ses résultats annuels 2021 et annonce son évolution stratégique vers les maladies neurologiques rares
Earnings Release Classification · 1% confidence The document is titled "THERANEXUS PUBLIE SES RÉSULTATS ANNUELS 2021 ET ANNONCE SON ÉVOLUTION STRATÉGIQUE VERS LES MALADIES NEUROLOGIQUES RARES" (Theranexus Publishes its 2021 Annual Results and Announces its Strategic Evolution towards Rare Neurological Diseases). It contains a detailed table of annual financial results for 2021 compared to 2020, including Income Statement items (Revenues, Operating Expenses, Net Income) and a cash position as of March 31, 2022. The text explicitly mentions that the "Résultats annuels 2021 ont été arrêtés par le conseil d'administration de la société le 22 avril 2022 et ont fait l'objet d'un rapport des Commissaires aux Comptes" (The 2021 annual results were approved by the company's board of directors on April 22, 2022, and have been the subject of a report by the Company's Auditors). Although it contains elements of a strategic update and management discussion, the core purpose and content revolve around the full-year financial performance disclosure, which aligns best with the comprehensive nature of an Annual Report (10-K) or a detailed financial disclosure. Given the presence of audited annual financial tables and the explicit mention of 'résultats annuels', it strongly suggests a comprehensive annual filing. Since the document is in French and appears to be a press release summarizing the annual results, it is most likely the French equivalent or a detailed summary preceding the formal 10-K filing, but the content depth points away from a simple Earnings Release (ER) or Report Publication Announcement (RPA). In the context of the provided codes, '10-K' is the closest match for a full annual financial report disclosure, even if this specific document is a press release summarizing it. FY 2021
2022-04-25 French
Theranexus publishes its 2021 full-year results And announces a shift of its strategic focus to rare neurological diseases
Earnings Release Classification · 1% confidence The document is titled 'THERANEXUS PUBLISHES ITS 2021 FULL-YEAR RESULTS AND ANNOUNCES A SHIFT OF ITS STRATEGIC FOCUS...'. It contains a detailed table of '2021 annual financial results' and an update on the cash position as of 31 March 2022. This content strongly indicates the release of periodic financial performance data. Since it covers the full year (2021), it relates to the Annual Report cycle. However, the document is structured as a press release announcing these results, including strategic commentary and financial highlights, rather than the comprehensive, audited 10-K filing itself. Furthermore, it explicitly mentions that the results were approved by the Board on April 22, 2022, and it is dated April 25, 2022. This timing and format align best with an Earnings Release (ER), which is the initial announcement of periodical financial results (key highlights). While it contains more detail than a typical ER, it is not the full 10-K. It is also not an Interim Report (IR) as it covers the full year. The presence of detailed financial tables and the announcement of full-year results makes ER the most appropriate classification over a simple RPA or RNS. FY 2021
2022-04-25 English
Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled "INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL SOCIAL" (Monthly Information relating to the total number of voting rights and shares comprising the share capital) and explicitly states the data as of March 31, 2022, referencing French commercial code and AMF regulations. This type of regular disclosure regarding the total number of shares and voting rights is a specific regulatory requirement, often related to capital structure updates or major shareholding notifications. Since it is a monthly update on the total number of shares and voting rights, it most closely aligns with 'Major Shareholding Notification' (MRQ) or a general regulatory filing (RNS). Given the specific nature of reporting total share capital and voting rights, which is a key component of monitoring significant ownership changes, MRQ is a strong candidate. However, the definition for MRQ is 'Notification of changes in significant share ownership levels (crossing thresholds)'. This document reports the absolute total, which is often a prerequisite for MRQ filings but is itself a distinct monthly capital disclosure. Since there is no specific code for 'Total Share Capital/Voting Rights Disclosure', and it is a mandatory regulatory disclosure, it fits best under the general 'Regulatory Filings' (RNS) or potentially 'Share Issue/Capital Change' (SHA) if interpreted broadly. Given the context of French regulatory filings, this specific monthly disclosure is often categorized separately, but among the provided options, it is a mandatory regulatory announcement. Because it is a direct, specific regulatory disclosure about the capital structure, and not a general announcement about a report, RNS is the most appropriate fallback for a specific, non-core financial report filing type.
2022-04-06 French
INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL SOCIAL
Share Issue/Capital Change Classification · 1% confidence The document is titled "INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL SOCIAL" (Monthly Information Relating to the Total Number of Voting Rights and Shares Comprising the Share Capital). It explicitly states the number of shares and theoretical voting rights as of a specific date (February 28, 2022), referencing French regulatory articles (Code de commerce and AMF regulations). This type of periodic disclosure regarding the total share capital and voting rights is a specific regulatory requirement. Among the provided codes, 'SHA' (Share Issue/Capital Change) is the closest fit as it deals directly with the composition of the share capital, although 'RNS' (Regulatory Filings) is a general fallback. Given the specific nature of reporting the total number of shares and voting rights, which is often linked to capital structure changes or mandatory periodic updates, SHA is the most precise classification, as it directly concerns the share count.
2022-03-23 French
À L'OCCASION DE LA JOURNÉE MONDIALE DES MALADIES RARES 2022, THERANEXUS DÉVOILE SES AVANCÉES SCIENTIFIQUES
Regulatory Filings Classification · 1% confidence The document is a press release dated February 28, 2022, detailing scientific advancements, funding milestones (Bpifrance payments), publication updates, and the initiation of a Phase I/II clinical trial for a drug candidate (BBDF-101). It also explicitly announces the 'Prochaine publication financière' (Next financial publication) scheduled for April 25, 2022, which will cover the 'Résultats financiers annuels 2021' (Annual financial results 2021). Since this document is an announcement about scientific progress and *precedes* the release of the full annual financial results, it is not the Annual Report (10-K) or the Interim Report (IR). It functions as a general corporate update highlighting key operational and scientific achievements, which often accompanies or precedes formal financial reporting periods. Given the content focuses heavily on R&D progress, partnerships, and funding, and it is a formal press release format, it best fits the category of a general corporate update or announcement. Since it is not a specific regulatory filing like DIRS, DIV, or DEF 14A, and it is not a transcript (CT) or a presentation (IP), the most appropriate classification for a detailed, non-standardized corporate update announcing progress and upcoming financial results is the general 'Regulatory Filings' fallback category (RNS), or potentially an Earnings Release (ER) if it contained summary financials, which it does not. However, because it is a detailed update on operations and science, and explicitly points to a future financial report, it is a broad corporate communication. Given the options, and the lack of specific financial summary data typical of an ER, RNS serves as the best fit for a detailed, non-scheduled corporate news release.
2022-02-28 French
THERANEXUS UNVEILS ITS SCIENTIFIC ADVANCES ON THE OCCASION OF WORLD RARE DISEASE DAY 2022
Regulatory Filings Classification · 1% confidence The document is a press release dated February 28, 2022, detailing scientific advances, platform milestones (NeuroLead), new publications, and the start of a Phase I/II clinical trial for Batten disease. It is not a formal regulatory filing like a 10-K or an IR. It is an announcement providing key operational and scientific updates, which aligns best with an Earnings Release (ER) if it were tied to a financial period, or more generally, a Regulatory Filing (RNS) if it doesn't fit other specific categories. However, it is a detailed update on company progress, including funding milestones and clinical trial starts, which often accompanies or precedes formal financial reporting. Crucially, it ends by announcing the 'Next financial publication' (2021 annual financial results) on April 25, 2022. This structure—providing operational updates and announcing the date of the formal financial report—is characteristic of a general corporate update or an Earnings Release (ER) that precedes the full financial report, or simply a general Regulatory Filing (RNS). Given the focus on scientific progress, clinical trials, and funding milestones, and the explicit announcement of the *next* financial publication date, it functions as a significant corporate update. Since it is not the full financial report (10-K or IR) nor a specific announcement like DIRS or DIV, the most appropriate general category for a significant, non-standard corporate update is RNS. If it were focused purely on financial highlights, ER would fit, but this is heavily weighted toward R&D and scientific news. I will classify it as RNS as a comprehensive regulatory/corporate update that doesn't fit the more specific operational codes.
2022-02-28 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.